Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyAmyloidosisTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Before my scan -I was told there are medicines for the heart cardiomyopathy - that slow it. Diflusinal isn’t that. Just curious if this is the standard.

October 8
 · 
Be the first to react
A MyAmyloidosisTeam Member

After my PYP scan I was started on Vyndamax.

October 13
A MyAmyloidosisTeam Member

I would suggest seeing another cardiologist ASAP. After my PYP SECT I was immediately placed on Vyndamax by my cardiologist.

October 13
MyAmyloidosisTeam

That's a really valid question, and it's completely understandable to want clarity on what treatments are available after a PYP scan confirms cardiac amyloidosis.

The type of amyloidosis matters a lot when it comes to treatment options. There are FDA-approved disease-modifying therapies specifically for ATTR-CM Show Full Answer

That's a really valid question, and it's completely understandable to want clarity on what treatments are available after a PYP scan confirms cardiac amyloidosis.

The type of amyloidosis matters a lot when it comes to treatment options. There are FDA-approved disease-modifying therapies specifically for ATTR-CM (transthyretin amyloid cardiomyopathy) that can slow the progression of amyloid buildup in the heart. These include:

- TTR stabilizers like tafamidis (Vyndamax) and acoramidis (Attruby), which prevent the TTR protein from breaking apart and forming deposits
- TTR-silencing therapies like vutrisiran (Amvuttra), which reduce TTR production using RNA technology Diflunisal is sometimes used off-label as a TTR stabilizer, but it is not an FDA-approved therapy for cardiac amyloidosis the way tafamidis or acoramidis are.

If the PYP scan confirmed ATTR-CM specifically, it may be worth having a direct conversation with your doctor — or seeking a second opinion from an amyloidosis specialist — about whether FDA-approved therapies like tafamidis or acoramidis might be appropriate for your situation.

It's also worth noting that AL amyloidosis has a different treatment approach, focusing on chemotherapy and immunotherapy to target the abnormal cells producing the damaging proteins. So confirming your exact subtype is key to understanding all your options.

October 8

Related Questions

View All
A MyAmyloidosisTeam Member asked a question 💭
PCB Florida 32413